Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Upgraded by StockNews.com to “Sell”

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) was upgraded by analysts at StockNews.com to a “sell” rating in a report released on Monday.

A number of other equities analysts have also issued reports on the company. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Actinium Pharmaceuticals in a research note on Thursday, September 7th. HSBC assumed coverage on Actinium Pharmaceuticals in a research note on Wednesday, September 6th. They set a “buy” rating and a $11.60 price objective for the company. Finally, B. Riley reiterated a “buy” rating and set a $20.00 price objective on shares of Actinium Pharmaceuticals in a research note on Tuesday, October 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $27.15.

Actinium Pharmaceuticals Stock Performance

Shares of Actinium Pharmaceuticals stock traded up $0.09 during trading on Monday, reaching $4.58. The company’s stock had a trading volume of 160,783 shares, compared to its average volume of 264,344. The stock has a market capitalization of $125.54 million, a P/E ratio of -2.53 and a beta of 0.31. Actinium Pharmaceuticals has a 1-year low of $4.30 and a 1-year high of $14.70. The company has a 50-day moving average price of $9.53.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. UBS Group AG raised its position in shares of Actinium Pharmaceuticals by 76.2% during the 4th quarter. UBS Group AG now owns 3,235 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 1,399 shares during the period. Quent Capital LLC purchased a new stake in shares of Actinium Pharmaceuticals during the 2nd quarter valued at approximately $37,000. Royal Bank of Canada raised its position in Actinium Pharmaceuticals by 38.5% in the second quarter. Royal Bank of Canada now owns 6,734 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 1,871 shares during the period. California State Teachers Retirement System purchased a new stake in Actinium Pharmaceuticals in the second quarter valued at approximately $64,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in Actinium Pharmaceuticals in the second quarter valued at approximately $83,000. 22.38% of the stock is currently owned by institutional investors and hedge funds.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.